Target | Drug Class | Compound Name | Pathology | Clinical Trial Identifier | Current Status |
---|---|---|---|---|---|
NOX1/4 | NOX inhibitors | GKT137831 | Idiopathic pulmonary fibrosis | NCT03865927 | Phase II |
Type 2 diabetes and albuminuria | NCT02010242 | Completed (phase III in preparation) | |||
Primary biliary cholangitis receiving ursodeoxycholic acid | NCT03226067 | Phase II | |||
NOS | NOS inhibitor | L-NMMA | GLP-2–mediated intestinal lipoprotein release | NCT03534661 | Phase I |
Non–small-cell lung cancer, malignant melanoma, head and neck squamous cell carcinoma (three more) | NCT03236935 | Phase I | |||
Metastatic triple negative breast cancer patients | NCT02834403 | Phase II | |||
2-Iminobiotin | Perinatal asphyxia | NCT01626924 | Phase II, recently terminated | ||
Out-of-hospital cardiac arrest | NCT02836340 | Phase II | |||
VAS203 | Traumatic brain injury | NCT02794168 | Phase III | ||
XO | XO inhibitor | Allopurinol (approved) | Chronic gout | — | — |
Ischemic stroke and transient ischemic attack | NCT02122718 | Phase IV | |||
Hypoxic-ischemic brain injury on neurocognitive outcome | NCT03162653 | Phase III | |||
Complications of renal transplant | NCT01332799 | Phase IV | |||
Congestive heart failure | NCT00181155 | Phase II | |||
Chronic heart failure | NCT00997542 | Phase IV | |||
Febuxostat (approved) | Gout | — | — | ||
Endothelial function, cardiovascular system, hypertension | NCT03395977 | N/A | |||
Hematologic malignancies of pediatric patients and adults | NCT03605212 | Phase II | |||
Chronic renal disease | NCT03425708 | Phase IV | |||
Topiroxostat | Diabetic nephropathy | NCT02327754 | Phase II | ||
Hyperuricemia | NCT02837198 | Phase II | |||
MAO | MAO inhibitor | Safinamide, selegiline | Parkinson disease | — | — |
Rasagiline (approved) | Macula-off retinal detachment | NCT02068625 | Phase IV | ||
Toloxatone (approved) | Depression | — | — | ||
Pirlindole (approved) | Depression, anxiety | — | — | ||
Phenelzine, isocarboxazid, tranylcypromine (approved) | Major depressive disorder | — | — | ||
Moclobemide (approved) | Addiction and major depression | — | — | ||
MPO | MPO inhibitor | AZD3241 | Parkinson disease | NCT01527695, NCT01603069 | Phase II |
Multiple system atrophy | NCT02388295 | Phase II (negative) | |||
AZD4831 | Heart failure | NCT03756285, NCT03611153 | Phase II |
GLP-2, glucagon-like peptide-2; L-NMMA, L-NG-monomethyl arginine.